Stereotaxis Reports 2024 Second Quarter Financial Results

Rhea-AI Summary

Stereotaxis (NYSE: STXS) reported its 2024 Q2 financial results, highlighting strategic progress despite commercial challenges. Key achievements include CE mark approval for GenesisX in Europe, 510(k) submission in the US, and progress on MAGiC regulatory reviews. The company also completed the acquisition of Access Point Technologies.

Q2 revenue was $4.5 million, down from $7.9 million in Q2 2023. System revenue was $0.2 million, while recurring revenue was $4.3 million. The gross margin was 74%. Operating expenses were $9.3 million, including $2.5 million in non-cash stock compensation. The company reported an operating loss of $6.0 million and a net loss of $5.8 million. Stereotaxis ended the quarter with $15.2 million in cash and no debt.

Positive

• CE mark approval for GenesisX in Europe
• 510(k) submission for GenesisX in the US
• Progress on MAGiC regulatory reviews in Europe and the US
• Acquisition of Access Point Technologies completed
• Gross margin of 74% in Q2 2024
• No debt on the balance sheet

Negative

• Q2 2024 revenue decreased to $4.5 million from $7.9 million in Q2 2023
• System revenue dropped to $0.2 million from $3.3 million in Q2 2023
• Operating loss increased to $6.0 million from $5.3 million in Q2 2023
• Net loss increased to $5.8 million from $5.0 million in Q2 2023
• Negative free cash flow of $3.1 million in Q2 2024
• Cash and cash equivalents decreased to $15.2 million

Insights

Financial Analyst

Stereotaxis' Q2 2024 results reveal significant challenges in the short term, but with potential for improvement. The $4.5 million revenue represents a substantial 43% decline year-over-year, primarily due to weak system sales. The $0.2 million system revenue is particularly concerning, down 94% from last year.

However, the company's recurring revenue remains relatively stable at $4.3 million, indicating a solid installed base. The 74% gross margin is commendable, suggesting efficient operations despite lower sales. The $15.2 million cash position provides some runway, but the $3.1 million negative free cash flow is worrisome if the trend continues.

The positive outlook for H2 2024, based on expected Genesis system deliveries and a strong late-stage pipeline, could signal a turnaround. Investors should closely monitor the company's ability to convert its backlog into recognized revenue in the coming quarters.

Medical Device Industry Expert

The introduction of GenesisX and progress with MAGiC represent significant milestones for Stereotaxis in the competitive surgical robotics market. Obtaining CE mark for GenesisX in Europe and submitting a 510(k) application in the US are important steps towards commercialization. These advancements could potentially accelerate adoption and drive future revenue growth.

The acquisition of Access Point Technologies (APT) is a strategic move that could enhance Stereotaxis' product portfolio and market position. However, the impact of this acquisition on financial performance remains to be seen.

The company's focus on innovation and regulatory approvals is commendable, but the current financial results suggest a challenging transition period. The success of GenesisX and MAGiC in the market will be critical for Stereotaxis to regain momentum and justify its ongoing investments in R&D and regulatory processes.

ST. LOUIS, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2024.

“We made significant progress over the last quarter on strategic innovation efforts that are establishing a solid foundation upon which to build a substantial and successful company,” said David Fischel, Chairman and CEO. “Key milestones achieved include successfully obtaining CE mark in Europe and submitting a 510(k) application in the US for GenesisX, substantial progress with regulatory reviews of MAGiC in Europe and the US, and closing the acquisition of Access Point Technologies (APT).” In a separate press release issued concurrent with this release, Stereotaxis introduced its next-generation robotic system GenesisX.

“We have attempted to realize our strategic transformation while maintaining commercial momentum and preserving financial strength. Commercial results for the first half of the year were below expectations with delayed recognition of revenue from our capital backlog. Our visibility into the second half of this year provides high confidence in significantly improved revenue and cash flow. Multiple Genesis systems are in transit to customers with revenue to be recognized and cash received at delivery. We have an active late-stage pipeline with additional orders expected near-term.

2024 Second Quarter Financial Results
Revenue for the second quarter of 2024 totaled $4.5 million, compared to $7.9 million in the prior year second quarter. System revenue of $0.2 million and recurring revenue of $4.3 million, compared to $3.3 million and $4.6 million, respectively, in the prior year second quarter. System revenue was weaker than expected due to delays in hospital construction schedules but does not reflect normalized expectations. Recurring revenue was in line with recent quarters.

Gross margin for the second quarter of 2024 was 74% of revenue. Operating expenses in the second quarter of $9.3 million include $2.5 million in non-cash stock compensation expense. Operating expenses in the quarter were impacted by higher acquisition-related legal costs and regulatory-related activities counteracted by the reversal of a historical accrued liability.   Excluding non-cash stock compensation expense, adjusted operating expenses in the quarter were $6.8 million, compared to $6.9 million in the prior year second quarter.

Operating loss and net loss for the second quarter of 2024 were ($6.0) million and ($5.8) million, respectively, compared to ($5.3) million and ($5.0) million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($3.5) million and ($3.3) million, respectively, compared with ($2.7) million and ($2.4) million in the previous year. Negative free cash flow for the second quarter was ($3.1) million.

Cash Balance and Liquidity
At June 30, 2024, Stereotaxis had cash and cash equivalents, including restricted cash, of $15.2 million and no debt.

Forward Looking Expectations
Stereotaxis expects greater than $14 million in revenue in the second half of this year given stable recurring revenue and current Genesis system shipments. Full year revenue is expected to be approximately equal to the previous year. These expectations do not incorporate contributions of revenue from APT or potential revenue from the launch of GenesisX and MAGiC.

Stereotaxis expects to end this year with approximately $13 million cash and no debt. Stereotaxis expects its balance sheet to allow it to advance its transformative product ecosystem to market, fund its commercialization, and reach profitability without the need for additional financing.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, August 12, 2024, at 4:30 p.m. Eastern Time. To access the conference call, dial 1-800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 7734844. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Company Contacts:                                                        
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery                                                        
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except share and per share amounts)	Three Months Ended June 30,								Six Months Ended June 30,
	2024				2023				2024				2023
Revenue:
Systems	$	240			$	3,313			$	2,852			$	5,134
Disposables, service and accessories		4,262				4,546				8,530				9,273
Total revenue		4,502				7,859				11,382				14,407
Cost of revenue:
Systems		187				2,703				2,087				4,400
Disposables, service and accessories		1,002				969				2,016				1,944
Total cost of revenue		1,189				3,672				4,103				6,344
Gross margin		3,313				4,187				7,279				8,063
Operating expenses:
Research and development		2,273				2,647				4,516				5,393
Sales and marketing		3,301				3,340				6,304				6,488
General and administrative		3,760				3,477				7,226				7,078
Total operating expenses		9,334				9,464				18,046				18,959
Operating loss		(6,021	)			(5,277	)			(10,767	)			(10,896	)
Other income (expense)		(3	)			27				(3	)			27
Interest income, net		191				293				430				565
Net loss	$	(5,833	)		$	(4,957	)		$	(10,340	)		$	(10,304	)
Cumulative dividend on convertible preferred stock		(325	)			(335	)			(656	)			(666	)
Net loss attributable to common stockholders	$	(6,158	)		$	(5,292	)		$	(10,996	)		$	(10,970	)
Net loss per share attributed to common stockholders:
Basic	$	(0.07	)		$	(0.07	)		$	(0.13	)		$	(0.14	)
Diluted	$	(0.07	)		$	(0.07	)		$	(0.13	)		$	(0.14	)
Weighted average number of common shares and equivalents:
Basic		84,570,738				81,049,211				84,025,335				78,787,652
Diluted		84,570,738				81,049,211				84,025,335				78,787,652

STEREOTAXIS, INC.
BALANCE SHEETS
(in thousands, except share amounts)	June 30,  2024				December 31,  2023
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	14,683			$	19,818
Restricted cash - current		481				525
Accounts receivable, net of allowance of $640 and $672 at 2024 and 2023, respectively		2,782				3,822
Inventories, net		9,284				8,426
Prepaid expenses and other current assets		842				676
Total current assets		28,072				33,267
Property and equipment, net		3,059				3,304
Restricted cash		-				219
Operating lease right-of-use assets		4,767				4,982
Prepaid and other non-current assets		116				137
Total assets	$	36,014			$	41,909
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	4,146			$	3,190
Accrued liabilities		2,698				2,972
Deferred revenue		4,950				6,657
Current portion of operating lease liabilities		458				428
Total current liabilities		12,252				13,247
Long-term deferred revenue		2,121				1,637
Operating lease liabilities		4,823				5,062
Other liabilities		54				43
Total liabilities		19,250				19,989
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 21,683 and 22,358 shares outstanding at 2024 and 2023, respectively		5,408				5,577
Stockholders' equity:
Common stock, par value $0.001; 300,000,000 shares authorized, 82,990,159 and 80,949,697 shares issued at 2024 and 2023, respectively		83				81
Additional paid-in capital		559,499				554,148
Treasury stock, 4,015 shares at 2024 and 2023		(206	)			(206	)
Accumulated deficit		(548,020	)			(537,680	)
Total stockholders' equity		11,356				16,343
Total liabilities and stockholders' equity	$	36,014			$	41,909

FAQ

What was Stereotaxis (STXS) revenue for Q2 2024?

Stereotaxis reported revenue of $4.5 million for the second quarter of 2024.

Did Stereotaxis (STXS) receive CE mark approval for GenesisX in Q2 2024?

Yes, Stereotaxis successfully obtained CE mark approval in Europe for GenesisX during the second quarter of 2024.

What was Stereotaxis (STXS) net loss for Q2 2024?

Stereotaxis reported a net loss of $5.8 million for the second quarter of 2024.

How much cash did Stereotaxis (STXS) have at the end of Q2 2024?

As of June 30, 2024, Stereotaxis had cash and cash equivalents, including restricted cash, of $15.2 million.

Did Stereotaxis (STXS) complete any acquisitions in Q2 2024?

Yes, Stereotaxis completed the acquisition of Access Point Technologies (APT) during the second quarter of 2024.